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S U M M A R Y
Background: The widespread resistance in Gram-negative bacteria has necessitated evaluation of the use
of older antimicrobials such as polymyxins. In the present studywe evaluated the different susceptibility
testing methods for polymyxins B and E against Gram-negative bacteria using the new Clinical and
Laboratory Standards Institute (CLSI) guidelines.
Methods: The susceptibility of 281 multidrug-resistant (MDR) Gram-negative bacteria (GNB) to
polymyxin B was evaluated, comparing broth microdilution (BMD; reference method), agar dilution,
E-test, and disk diffusion. Disk diffusion testing of polymyxin B was also performed against 723 MDR
GNB.
Results: Twenty-four of 281 (8.5%) isolates were found to be resistant to polymyxin B by the reference
BMDmethod. The rates of very major errors for agar dilution and E-test (for polymyxin B) were 0.7% and
1%, respectively, and those for disk diffusion (for polymyxin B and polymyxin E) were 1% and 0.7%,
respectively. For the 257 isolates found sensitive by reference BMD, the rates of major errors by agar
dilution and E-test (for polymyxin B) were 2.4% and 0%, respectively, and those for disk diffusion
(polymyxin B and polymyxin E) were 0% and 0.7%, respectively. Twenty-six (3.6%) of the 723 Gram-
negative isolates were resistant to polymyxin B by disk diffusion.
Conclusion: The E-test and agar dilution methods showed good concordance with BMD. The disk
diffusion method can be useful for initial screening in diagnostic laboratories.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The inexorable rise of antibiotic resistance and the paucity of
new antimicrobials have led to a renewed interest in the use of the
polymyxin group of antibiotics for the treatment of infections due
to multidrug-resistant (MDR) bacteria.1,2 Strains of Acinetobacter
baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae that
exhibit resistance to almost all available antibiotics except
polymyxins, have emerged as a common cause of hospital-
acquired infections in critically ill patients.3,4 Polymyxins are
multicomponent polypeptide antibiotics that act primarily on the
Gram-negative bacterial cell wall, leading to rapid permeability
changes in the cytoplasmic membrane and ultimately to cell
death.5 Polymyxin E (colistin) and polymyxin B have occasionally* Corresponding author. Tel.: +91 11 26189000ext. 1169; fax: +91 11 26106826.
E-mail address: purvamathur@yahoo.co.in (P. Mathur).
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.09.001been used to treat infections caused by Gram-negative bacteria
(GNB) that are resistant to aminoglycosides, cephalosporins, anti-
Pseudomonas penicillins, quinolones, monobactams and carbape-
nems.6,7 Thus, they are being used as a last resort drug for the
treatment of life-threatening infections.
The increased need for polymyxin treatment in critically ill
patients in the intensive care unit (ICU) has also created a pressing
need for up-to-date susceptibility data. The in vitro susceptibility
testing of polymyxin group antimicrobials is hampered by several
different factors. The accuracy of the disk diffusion assay is
unsatisfactory because polymyxins diffuse poorly into agar, and
consequently no reliable correlation of zone diameters and
minimum inhibitory concentrations (MICs) has been found in
some studies.8 The interpretative criteria for quantitative in vitro
testing also differ between nations.8 Recently, the Clinical and
Laboratory Standards Institute (CLSI) approved a standard docu-
ment for the testing of polymyxins against P. aeruginosa,
Acinetobacter spp and a few other non-fermenters using dilutionses. Published by Elsevier Ltd. All rights reserved.
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disk susceptibility testing of polymyxins were published by the
CLSI.10 However, there is still no consensus regarding the break-
points for deﬁning resistance to polymyxins. Since relatively few
surveys of antibiotic resistance have been performed on this group
of antimicrobials, reliable data on true resistance levels are also
lacking. Considering the increasing use and demand for poly-
myxins and the relative paucity of data regarding resistance, we
evaluated different susceptibility testing methods for this class of
antimicrobial in the present study.
Methods
The study was performed over a period of 1 year (October 2007
to September 2008) at the Microbiology Laboratory of the 190-bed
level-1 Trauma Centre of the All India Institute of Medical Sciences
(AIIMS), New Delhi, India. AIIMS is a 2500-bed, tertiary care,
teaching and referral hospital.
The studywas conducted in two parts. The ﬁrst part of the study
– evaluation of methodologies for determination of polymyxin B
MICs – was carried out from October 2007 to March 2008.
Representative MDR GNB isolated from the samples of patients
admitted to the ICUs and wards of the AIIMS Hospital and its
Trauma Centre (medical, pediatric, surgical, gastroenterology,
oncology, nephrology, neurosurgery, cardiothoracic surgery and
trauma care ICU) were included. Various techniques for the
antimicrobial susceptibility testing of polymyxin B and polymyxin
E (determination of MICs by broth microdilution (BMD), agar
dilution, and E-test, along with disk diffusion testing) were
evaluated in this part of the study.
The second part of the study – polymyxin B susceptibility
testing – was done on consecutive MDR GNB isolated from various
clinical samples of patients admitted to the ICUs of the Trauma
Centre, AIIMS, from April to September 2008. Antimicrobial
susceptibility testing for polymyxin B was performed on these
isolates using the disk diffusion technique.
Evaluation of methodologies for the determination of polymyxin B
MICs
In this part of the study, a total of 281 representative MDR
GNB isolated from clinical samples as described above were
included. The isolates represented various genera of Enterobac-
teriaceae and non-fermenters. MDR was deﬁned as resistance to
two or more of the most commonly used antimicrobial classes for
the treatment of the indicated infection. All these GNB were
identiﬁed by conventional microbiological methods11 and by the
Vitek 2 identiﬁcation system (BioMerieux, France), using ID-GN
cards. Only one isolate per patient was included. The clinical
source of the isolates and patient ward were recorded.
Antimicrobial susceptibility testing of these isolates was
performed using the Vitek 2 system and the disk diffusion
method, according to CLSI guidelines.12 The following antibiotics
were tested by the disk diffusion method: ceftazidime (30 mg),
ceftazidime/clavulanic acid (30/10 mg), cefotaxime (30 mg),
ceftriaxone (30 mg), cefepime (30 mg), cefoperazone/sulbactam
(75/30 mg), piperacillin/tazobactam (100 mg/10 mg), ticarcillin/
clavulanic acid (75/10 mg), amikacin (30 mg), gentamicin
(10 mg), imipenem (10 mg), ertapenem (10 mg), meropenem
(10 mg), and ciproﬂoxacin (5 mg) (BBLTM, BD, USA). MICs were
determined using the AST GN 13 cards by the Vitek 2 advanced
expert system (BioMerieux, France). All the isolates were stored
at 70 8C until further testing.
An evaluation of polymyxin B and polymyxin E susceptibility
testing methods was done using these 281 isolates. For this, the
following isolates were used as controls: Escherichia coli ATCC25922, P. aeruginosa ATCC 27853, K. pneumoniae ATCC 700603, A.
baumannii ATCC 19606, Stenotrophomonas maltophilia ATCC 13636
and Burkholderia cepacia ATCC 25608.
MIC determination
The MIC of polymyxin B was determined for the 281 isolates by
the following methods:
Broth microdilution (BMD). BMD with cation-adjusted Mueller–
Hinton broth (BBL-Becton Dickinson) was performed in accor-
dance with the CLSI recommendations and was used as the
reference method.9,10,13 Polymyxin B concentrations ranging from
0.0015mg/ml to 1024 mg/ml were tested by the BMDmethod. The
MIC was deﬁned as the lowest concentration of polymyxin B at
which no visible growth was obtained using CLSI recommended
incubation conditions.13 A polymyxin B MIC of 2mg/ml was
taken as the breakpoint for susceptibility.14,15 Since to-date, the
CLSI susceptibility breakpoints of polymyxin B have been available
only for P. aeruginosa, A. baumannii and some other non-
fermenters,16 we used the same breakpoints for Enterobacteriaceae
and other genera not covered in the CLSI document, as has been
done in a few other studies.14,15
E-test. The MIC of polymyxin B was determined by the E-test
method, performed according to the manufacturer’s instructions
(AB Biodisk, Solna, Sweden). The MIC was read where inhibition of
growth intersected the E strip. When small colonies grew within
the zone of inhibition or a haze of growth occurred around theMIC
end-point, the highest MIC intersection was recorded. The MICs of
the E-test were rounded up to the next highest two-fold dilution
for comparison of results with the reference method.17
Agar dilution. TheMIC of polymyxin Bwas also determined by agar
dilution method,13 in which polymyxin B powder (Sigma Aldrich,
USA) in solution was added to molten Mueller–Hinton agar (BD,
USA) to provide two-fold dilutions ranging from 0.25 mg/ml to
1024mg/ml. Bacterial suspensions were applied on the agar plates
and the results were read following incubation at 35 8C for 18–
20 h.
Disk diffusion
Disk diffusion testing was done using 300 U polymyxin B disk
and 10 mg colistin disk (BBL, BD, USA), according to the CLSI
guidelines.10 The disk zone diameters were interpreted according
to the CLSI guidelines for colistin (resistant 10 mm and
susceptible 11 mm) and polymyxin B (resistant 11 mm and
susceptible 12 mm).10
The bacterial inoculum was adjusted for disk diffusion, BMD,
E-test, and agar dilution methods strictly according to CLSI
guidelines18 using a nephelometer (BioMerieux, France). All four
methods were performed simultaneously for each isolate.
For comparison of performance, BMD was taken as the
reference method. Agreement between BMD, agar dilution, and
the E-test was deﬁned as MICs that differed by 1 log2 dilution or
less. Categorical agreement was deﬁned as test results within the
same susceptibility. Errors were ranked as follows: very major error,
false-susceptible result by the disk diffusion/agar dilution/E-test;
major error, false-resistant result produced by the disk diffusion/agar
dilution/E-test. Unacceptable levels were taken as 1.5% for very
major errors and 3% for major errors, as recommended by CLSI
document M23-A2.19
Repeat testing
A repeat testing of BMD, agar dilution, E-test, and disk diffusion
of polymyxins B and Ewas done for all strains displaying resistance
to polymyxin by the reference BMD method. Individual test
Table 1
Sources of the organisms included in the ﬁrst part of the study
Organisms Source Total
BAL Blood Pus Urine CSF Tips
Pseudomonas spp 63 21 5 1 1 91
Acinetobacter spp 64 18 2 6 1 91
Klebsiella spp 23 38 1 2 2 66
Enterobacter spp 5 2 2 9
Escherichia coli 1 1 7 9
Burkholderia spp 3 5 8
Stenotrophomonas spp 2 1 3
Proteus spp 2 2
Morganella spp 1 1
Providencia spp 1 1
Total 162 87 4 22 3 3 281
BAL, bronchoalveolar lavage; CSF, cerebrospinal ﬂuid.
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reproducibility if they displayed very major or major errors.
Polymyxin B susceptibility of clinical isolates
In the second part of our study, consecutive MDR GNB obtained
from clinical samples of patients admitted over a period of 6
months, as mentioned above, were included. Only one isolate per
patient was included in the study. The clinical source of the
isolates, ward of the patient, and antibiotic susceptibility proﬁle of
these isolates was recorded. The identiﬁcation and antimicrobial
susceptibility testing of the isolates was done as described in the
ﬁrst part of the study. All these isolates were subjected to
polymyxin B disk diffusion susceptibility testing (using 300 U
polymyxin B disks) as per themethod described above. The isolates
showing a polymyxin B-resistant phenotype were tested twice by
the disk diffusion method. ATCC strains (as detailed above) were
used as controls for disk diffusion testing.Table 2
Comparison of E-test, agar dilution, and disk diffusion methods against the reference m
Organisma (N=24) Broth microdilution
(mg/ml)
E-test (mg/m
Burkholderia cepacia >1024 >1024
Burkholderia cepacia >1024 >1024
Burkholderia cepacia >1024 >1024
Burkholderia cepacia >1024 >1024
Burkholderia cepacia >1024 >1024
Burkholderia cepacia >1024 >1024
Burkholderia cepacia >1024 >1024
Stenotrophomonas maltophilia 256 256
Stenotrophomonas maltophilia 8 8
Stenotrophomonas maltophiliab 8 64
Pseudomonas aeruginosa >1024 >1024
Pseudomonas aeruginosa >1024 >1024
Pseudomonas aeruginosa >1024 >1024
Acinetobacter baumannii >1024 >1024
Acinetobacter baumanniic 8 8
Acinetobacter baumanniid 8 2
Klebsiella pneumoniae >1024 >1024
Klebsiella pneumoniaee 16 0.5
Klebsiella pneumoniae 8 8
Proteus mirabilis 1024 >1024
Proteus mirabilis 1024 >1024
Morganella morgannii 1024 >1024
Providencia spp >1024 >1024
Enterobacter sppf 8 1
a Total number of bacteria tested by all methods: 281; polymyxin-resistant isolates:
b Although theMICs differed by>3-fold between the reference and the other twometh
Therefore, the results were not included in the ‘error’ category.
c Very major error for polymyxin B and colistin disk diffusion.
d Very major error for E-test, agar dilution and polymyxin B disk diffusion.
e Very major error for E-test, agar dilution and polymyxin B and E disk diffusion.
f Very major error for E-test.Results
Evaluation of the methodologies for the determination of MIC
A total of 281 MDR GNB were included in the ﬁrst part of the
study. The distribution and sources of these isolates are shown in
Table 1. All these isolates were extended-spectrum b-lactamase
(ESBL)-positive and were also resistant to aminoglycosides and
ﬂuoroquinolones. Of the 281 isolates, 126 (45%) were resistant to
all available antimicrobials.
Polymyxin B MICs
The MIC of polymyxin B was determined by three methods as
described above. Of the 281 isolates, a total of 24 (8.5%) were
resistant to polymyxin B by the reference BMDmethod. There was
agreement (1 log2 dilution difference or less) of MICs by all three
methods in 20 of the 24 resistant strains. Details of the performance of
the MIC methodologies for these 24 isolates are shown in Table 2.ethod in polymyxin B-resistant bacteria
l) Agar dilution
(mg/ml)
Polymyxin B disk
diffusion (mm)
Colistin disk
diffusion (mm)
>1024 0 0
>1024 0 0
>1024 0 0
>1024 0 0
>1024 0 0
>1024 0 0
>1024 0 0
256 0 0
16 0 0
128 0 0
>1024 0 0
>1024 0 0
>1024 0 0
>1024 0 0
8 14 13
2 16 0
>1024 0 0
2 14 12
8 0 0
>1024 0 0
>1024 0 0
>1024 0 0
>1024 0 0
8 0 0
24.
ods, the isolate was found to be resistant by all theMICmethods and disk diffusion.
Table 3
Agreement of polymyxin MICs among the three test methods
Categorical
agreement
Agreement
(1 log2
dilution
variation)
>1 log2
dilution
variationa
Major
error
Very
major
error
BMD and E-test 140 (50) 115 (41) 23 (8) 0 3 (1)
BMD and
agar dilution
107 (38) 141 (50) 24 (8.5) 7 (2.4) 2 (0.7)
Results are n (%). MIC, minimum inhibitory concentration; BMD, broth microdilu-
tion.
a For isolates in this category, the MIC differed by 1 log2-fold. However, the
interpretation was either sensitive or resistant by all three methods, although the
MICs differed by 1 log2-fold between the methods.
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the E-test. However, seven isolates displayed resistance by the agar
dilution method (categorized as major error). The MIC90 of
polymyxin B by broth microdilution was 1mg/ml. The overall
agreement level between the reference BMD and other two MIC
methods is shown in Table 3. It was observed that the MICs by E-
test were generally lower than by BMD, and agar dilution MICs
were higher than by BMD. The rates of verymajor andmajor errors
were within CLSI acceptable limits.
Disk diffusion testing
Of the 24 isolates resistant by the BMD, two were found to be
sensitive by colistin and three were sensitive by polymyxin B disks
(very major errors; Table 2). Of the three isolates sensitive by
polymyxin B disks, two were also sensitive by E-test (Table 2).
However, one strain of A. baumanniiwas resistant by all three MIC
methods. This strain was also sensitive by colistin disk. Of the 257
strains sensitive by BMD, all were sensitive by polymyxin B disk.
However, two displayed resistance with colistin (categorized as
major error). Thus, the rates of very major errors for polymyxin B
and E disks were 1% and 0.7%, respectively, whereas the rates of
major errors were 0% and 0.7%, respectively. In 247 of the 257
strains, the zone diameter of polymyxin B was 1–5 mm larger than
that of colistin. In nine strains, their zone diameterswere equal and
in one strain, the zone diameter of colistin was greater than that of
polymyxin B.
The MICs and disk zone diameters for control strains were
within the range proposed by the CLSI.
Polymyxin B susceptibility in clinical isolates
A total of 723 consecutive GNB obtained from various clinical
specimens were included in this part of the study. Of these, P.
aeruginosawas themost common (n = 409 (57%)). The distribution,
clinical source and antibiotic susceptibility of these isolates are
shown in Table 4. Acinetobacter spp had the highest prevalence of
resistance to all antimicrobial classes. Of these 723 organisms, 697
(96.4%) were found to be sensitive to polymyxin B by the disk
diffusion method. Of the 26 isolates found to be resistant to
polymyxin, 14 were P. aeruginosa, seven were B. cepacia and ﬁve
were S. maltophilia (Table 4).
Discussion
The emerging multi-drug resistance in nosocomial GNB has
necessitated the use of parenteral polymyxins for the treatment of
life-threatening infections. Therefore, there is an increased need
for reliable susceptibility testing methods to predict clinical
response. Susceptibility testing for polymyxin B and E is plagued
with problems, such as the lack of consensus regarding break-
points for resistance between the CLSI, the British Society for
Antimicrobial Chemotherapy (BSAC), the French Socie´te´ Franc¸aise
B. Behera et al. / International Journal of Infectious Diseases 14 (2010) e596–e601e600de Microbiologie (SFM), and the German Deutsches Institut fu¨r
Normung (DIN); the reported poor diffusion of polymyxins in the
agar; and the lack of correlation between different dilution
methods, as well as lacunae in studies done on this group of
antimicrobials, most of which have been done using colistin.2,15,17
Our institute has a very high prevalence of ESBL-producing GNB20
and metallo-b-lactamase-producing P. aeruginosa.21 At the Trau-
ma Centre of AIIMS, patients admitted to the ICUs frequently suffer
from ventilator-associated pneumonia due to MDR P. aeruginosa
and Acinetobacter spp, necessitating the use of intravenous/
aerosolized polymyxins.
We conducted the present study to evaluate the methods of
MIC detection for polymyxin B and to ﬁnd the level of polymyxin
B resistance in GNB at our hospital. Our initial aim was to assess
the performance of agar dilution and E-test as well as of the
simple disk diffusion methods against the reference BMD. All the
isolates found to be sensitive by the reference BMD were also
detected to be sensitive by the E-test (speciﬁcity 100%). However,
the agar dilution method (major error rate of 2.4%) had a
speciﬁcity of 97.6%. The sensitivity of the E-test (21/24 detected
as resistant) and agar dilution (22/24 detected as resistant) were
87.5% and 92%, respectively. A concordance of 99% was found
between the E-test and BMD (three very major errors) and 97%
was found between agar dilution and BMD (seven major and two
very major errors). The resistant isolates included B. cepacia,
Proteus mirabilis and Providencia spp, which are known to be
intrinsically resistant to polymyxins.2 Similarly, the sensitivities
of polymyxin B and polymyxin E disk diffusion testing were 92%
and 87.5%, respectively, and the speciﬁcities were 100% and 99%,
respectively. A concordance of 99% and 98.5% was found between
polymyxin B and polymyxin E disk diffusion, respectively, with
BMD.
Of the limited number of studies on polymyxin resistance, the
majority have been done on Pseudomonas and Acinetobacter spp.
The rate of resistance in these genera is reported to vary from 0% to
5% for Pseudomonas and 0% to 19% for Acinetobacter. However,
different interpretative guidelines have been used in these studies
making it difﬁcult to compare the results.15,17,22 Only one study
has reported resistance in Stenotrophomonas spp, Morganella spp,
and Klebsiella spp.15 Due to the emergence of pan-resistant
Klebsiella and other genera, polymyxins are being used as life-
saving antimicrobials in serious infections caused by these
organisms. In our study, isolates of Acinetobacter, Pseudomonas,
Stenotrophomonas, Morganella, Klebsiella, Enterobacter and
Burkholderia were found to be resistant to polymyxin by
quantitative MIC and disk diffusion techniques. A limitation of
our study was the relatively small number of organisms
representing some genera. Therefore, more studies are needed
to assess the true magnitude of polymyxin resistance in various
Gram-negative organisms.
The E-test has been evaluated for polymyxin susceptibility
testing in a few studies. A concordance of 98.2% between BMD and
the E-test for colistin, with 1.7% very major error 22 was found in
Acinetobacter spp. in one study.22 In another study comparing the
E-test and agar dilution for colistin, a concordance of 87% was
found with 5% very major errors and 9% major errors.15 A
concordance of 90% was found between the E-test and BMD for
polymyxin B in 109 isolates of P. aeruginosa.17
To our knowledge, this is the ﬁrst study comparing BMD, agar
dilution, and the E-test for polymyxin B along with disk diffusion
for polymyxins B and E for a range of MDR Gram-negative genera
using the new CLSI guidelines. We found a very good concor-
dance between the reference BMD and the E-test. Although
determination of MIC by BMD is considered to be the optimum
method, it is impractical and cumbersome for most busy
clinical microbiology laboratories. Therefore, the E-test couldbe used as a viable alternative, since it is very easy to perform and
interpret.
We also found a good concordance between agar dilution and
BMD in our study. In a study on P. aeruginosa from cystic ﬁbrosis
patients, agar dilution was taken as the gold standard and it was
found that BMD was most reliable at a susceptibility breakpoint
of 4 mg/l, with a speciﬁcity of 91% and sensitivity of 89%.8
However, in agreement with Hogardt et al.,8 a slightly higher
polymyxin B MIC (1–2 log2 dilution difference) was seen with
agar dilution as compared to the BMD in our study. Nevertheless,
the method is suitable for batch testing of a large number of
strains. We also found good concordance of disk diffusion results
by polymyxin B and colistin disks. Since disk diffusion was found
to have an acceptable rate of errors, we used this simple method
for screening a larger number of GNB in the second half of the
study. We found a resistance rate of 3.6% by the disk diffusion
method. However, of the resistant strains, 27% were B. cepacia,
which are intrinsically resistant to polymyxins. A signiﬁcant
ﬁnding was the detection of polymyxin resistance (3%) in strains
of Pseudomonas. A limitation of our study was that we did not
determine the polymyxin MICs for these isolates of P. aeruginosa.
However, all the isolates were tested twice and there was no zone
around polymyxin B disks. Therefore, we presume these to be
actually resistant to polymyxin B, based on our results in the
initial part of this study.
To conclude, in view of the paucity of available antimicrobials
and the potential toxicity of polymyxin group antimicrobials, their
clinical use must be based on validated in vitro susceptibility
results. The disk diffusion method can be used for initial screening
in busy hospital laboratories.
Acknowledgements
We thank Ms Neelu, Ms Sweety, Ms Raj Rani, Mr Ashwini and
Mr Trilok for their technical assistance.
Conﬂict of interest: No conﬂict of interest to declare.
References
1. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous
and aerosolized polymyxins for the treatment of infections in critically ill
patients: a review of the recent literature. Clin Med Res 2006;4:138–46.
2. Arnold TM, Forrest GN, Messmer KJ. Polymyxin antibiotics for Gram-negative
infections. Am J Health Syst Pharm 2007;64:819–26.
3. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassoupoulou P, Micha-
lopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-nega-
tive bacteria. BMC Infect Dis 2005;5:24.
4. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin
treatment in patients with ICU-acquired infections caused by multi-resistant
Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol
Infect 2005;11:115–21.
5. EvansME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for
emerging multi-resistant Gram-negative bacteria. Ann Pharmacother 1999;
33:960–7.
6. Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Manrique EI, et al.
Intravenous colistin as therapy for nosocomial infections caused by multi-
drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect
Dis 1999;28:1008–11.
7. Littlewood JM, Koch C, Lambert PA, Hoiby N, Elborn JS, Conway SP, et al. A ten
year review of colomycin. Respir Med 2000;94:63–71.
8. HogardtM, Schmoldt S, GotzfriedM, Adler K, Hessemann J. Pitfalls of polymyxin
antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from
cystic ﬁbrosis patients. J Antimicrob Chemother 2004;54:1057–61.
9. Clinical and Laboratory Standards Institute. Performance standards for antimi-
crobial susceptibility testing. Seventh informational supplement M100-S15.
Wayne, PA: CLSI; 2005.
10. Clinical and Laboratory Standards Institute. Performance standards for antimi-
crobial susceptibility testing. Seventh informational supplement M100-S17.
Wayne, PA: CLSI; 2007.
11. Collee JG, Diguid JP, Fraser AG. Mackie and McCartney practical medical
microbiology, 14th ed., Edinburgh: Churchill Livingstone; 1996.
12. Clinical and Laboratory Standards Institute. Performance standards for antimi-
crobial susceptibility testing. 16th informational supplement M100-S16.
Wayne, PA: CLSI; 2006.
B. Behera et al. / International Journal of Infectious Diseases 14 (2010) e596–e601 e60113. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial
susceptibility tests for bacteria that grow aerobically. 15th informational sup-
plement, 6th ed., M7-A6. Wayne, PA: CLSI; 2003.
14. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of
polymyxin B against 54731 clinical isolates of Gram-negative bacilli: report
from the SENTRY antimicrobial surveillance programme (2001–2004). Clin
Microbiol Infect 2006;12:315–21.
15. Tan TY, Ng SY. Comparison of E-test, Vitek and agar dilution for susceptibility
testing of colistin. Clin Microbiol Infect 2007;13:541–4.
16. Clinical and Laboratory Standards Institute. Performance standards for antimi-
crobial susceptibility testing. 19th informational supplement. Vol. 29 (3).
Wayne, PA: CLSI; 2009.
17. van der Heijden IM, Levin AS, De Pedri EH, Fung L, Rossi F, Duboc G, et al.
Comparison of disc diffusion, E-test and broth microdilution for testing sus-
ceptibility of carbapenem-resistant P. aeruginosa to polymyxins. Ann Clin
Microbiol Antimicrob 2007;6:8.18. National Committee for Clinical and Laboratory Standards.Methods for dilution
antimicrobial susceptibility tests for bacteria that grow aerobically. Approved
standard M7-A5, 5th ed. Wayne, PA: NCCLS; 2002.
19. National Committee for Clinical and Laboratory Standards. Development of in
vitro susceptibility testing criteria and quality control parameters. Approved
standard M23-A2. Wayne, PA: NCCLS; 1981.
20. Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum beta
lactamase producing Gram-negative bacteria in a tertiary care hospital. Indian J
Med Res 2002;115:153–7.
21. Behera B, Das A, Mathur P, Kapil A. High prevalence of carbapenem resistant
Pseudomonas aeruginosa at a tertiary care centre of India. Are we under
reporting? Ind J Med Res 2008;128:324–5.
22. Arroyo LA, Garcia-Curiel A, Pachon-lbanez ME, Llnoas AC, Ruiz M, Pachon J,
et al. Reliability of the E-test method for detection of colistin resistance
in clinical isolates of Acinetobacter baumannii. J Clin Microbiol 2005;43:
903–5.
